Clinical and Laboratory Positive Predictive Value of Symptom Management of STI in Iran: A Community-Based Survey

authors:

avatar Mohammad Fararouei ORCID 1 , avatar Zeinab Deldar ORCID 2 , avatar Samira Pourrezaei ORCID 3 , avatar Victoria Momenabadi ORCID 4 , avatar Masoumeh Sadat Mousavi ORCID 5 , *

HIV/AIDs Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
School of Public Health, Bam University of Medical Sciences, Bam, Iran
Department of Public Health, Eghlid Branch, Islamic Azad University, Eghlid, Iran

how to cite: Fararouei M, Deldar Z, Pourrezaei S, Momenabadi V, Mousavi M S. Clinical and Laboratory Positive Predictive Value of Symptom Management of STI in Iran: A Community-Based Survey. Nephro-Urol Mon. 2024;16(4):e148625. https://doi.org/10.5812/numonthly-148625.

Abstract

Background:

The correct diagnosis of sexually transmitted infections (STIs) is the first step in the monitoring and management of these diseases.

Objectives:

This study was conducted to investigate the clinical and laboratory positive predictive value (PPV) of STI symptom management in Iran.

Methods:

This cross-sectional study was conducted on 5986 individuals (aged 18 to 50 years) from the general population of Marovdasht (Iran) in several stages: (1) self-reported symptoms of sexually transmitted diseases, (2) evaluation by a doctor, and (3) laboratory examination.

Results:

Among the population sample, 686 (17.68%) individuals reported at least one of the predefined symptoms. The clinical-based PPV of syndromes in men and women were 67.74 (62.34 - 73.14) and 85.36 (82.76 - 87.96), respectively. In men and women, the highest PPV was observed for abnormal discharge from the anus 32.35 (25.35 - 39.35) and abnormal secretions from the cervix 59.39 (56.39 - 62.39), respectively. The laboratory-based PPV for men and women was 0 and 5.04 (3.04 - 7.4), respectively.

Conclusions:

The clinical and laboratory-based PPV of STI symptoms in the general population is extremely low. Accordingly, a syndromic-based screening or monitoring approach for STIs is not a reliable tool for screening or monitoring in the Iranian general population. We suggest focusing on special (core) groups for monitoring STIs using laboratory-based methods.

1. Background

Sexually transmitted infections (STIs) are common infectious diseases and public health challenges worldwide. Among the many aspects of epidemiology and controlling STIs, timely diagnosis and treatment are highly important (1). However, in developing countries and populations with limited laboratory services, the diagnosis of STIs is challenging, expensive, and often inaccessible (2).

A widely used alternative to laboratory-based diagnosis is symptom-based diagnosis. The symptom-based diagnosis approach for STIs involves identifying predefined syndromes using a flowchart designed for the diagnosis of these diseases (3). These charts are simple, easy to implement by non-STI specialists, and can be integrated into primary health care settings, allowing for contact tracing, partner management, and counseling (4). Symptom-based treatment and management are also fast and cost-efficient when laboratory tests are not available, allowing for immediate treatment to begin (5). However, the symptom-based approach to STIs surveillance often leads to overdiagnosis and overtreatment (6). There is no consensus on the performance of syndrome-based STI diagnosis, as several studies from different countries have reported conflicting results (2). Symptom management of STIs using algorithms based on self-reported symptoms is sometimes the only available option in many low- and middle-income countries. However, our knowledge about the validity of this approach is severely limited (1, 3).

Considering the advantages of the syndrome-based strategy in diagnosing STIs in developing countries, there is a long-standing need to evaluate the validity of this approach (6, 7).

2. Objectives

The aim of this population-based study (urban, rural) is to determine whether this approach is a suitable tool for screening STIs in the general population of Iran by measuring the clinical and laboratory positive predictive values (PPV) of the symptom-based approach for the diagnosis of STIs in Iran.

3. Methods

3.1. Setting

In 2019, this cross-sectional study was conducted on 3879 individuals (aged 18 - 50 years) who were randomly selected from the general population of Marvdasht county, Iran.

3.2. Data Collection

The study was conducted in three steps: (1) self-reporting of STI symptoms, (2) evaluation of the patients by a trained physician, and (3) laboratory confirmation of the clinically diagnosed patients (Figure 1). More details about sampling and methods have been provided in previous studies (8, 9).

Step by step process of studying
Step by step process of studying

3.3. Laboratory Testing Methods

PCR and NAAT (PCR) diagnostic tests were used in this study.

3.4. Data Analysis

Descriptive statistics, including mean, median, and percentage, were used to summarize the data. The positive predictive value of the symptom-based diagnosis strategy was defined. Data analysis was performed using STATA version 13.1.

4. Results

4.1. The Prevalence of Sexually Transmitted Infections-Associated Symptoms, Clinical Exam, and Laboratory Test Results

In total, 3879 individuals with an average age of 34.28 ± 8.74 participated in this study. Among the population sample, 686 (17.68%) individuals reported at least one of the predefined symptoms, of which 217 (9.7%) were male and 469 (28.7%) were female. Among the patients who were referred to the physician, 192 (68.82%) were confirmed by the doctor to have symptoms. The details are presented in Table 1.

Table 1.

Summary of the Results a

Letter NameTotal People Aged 18 - 50Men 18 to 50 Years OldWomen 18 to 50 Years Old
Total 6813 (57.92)3520 (51.67)3293 (48.33)
Entered the study 3879 (56.94)2243 (63.86)1637 (49.71)
Having at least one of the syndromes678 (17.48)217 (9.67)461 (28.16)
Referred to the physician 279 (41.15)62 (7.37)164 (35.57)
Confirmed by a physician 192 (68.82)42 (67.74)140 (85.37)
Referred to the physician128 (66.67)19 (45.24)109 (77.66)
Confirmed by a laboratory6 (4.69)06 (5.50)

The results of Table 2 show that most of the participants in the study are married and have a high school education. Additionally, 69.96% of the participants reported being sexually active, and their average age is 34.28 years.

Table 2.

Demographic Characteristics of the Participants a

VariablesMaleFemaleTotal
Residency
Urban1119 (49.9)961 (58.7)2080 (53.62)
Rural1124 (50.1)675 (41.3)1799 (46.37)
Marital status
Single737 (32.9)334 (20.3)1071 (27.84)
Married1493 (66.7)1208 (75.2)2701 (70.24)
Widow/divorced9 (0.4)64 (4)73 (1.89)
Education
Literate39 (1.8)85 (5.2)124 (3.30)
Primary372 (17.5)410 (25.2)782 (20.84)
Secondary555 (26.1)290 (17.8)845 (22.52)
High school698 (32.8)511 (31.4)1209 (32.22)
Academic461 (21.7)331 (20.3)792 (21.10)
Job
Worker308 (14.8)-308 (8.30)
Employee170 (8.2)81 (5)251 (6.76)
Farmer298 (14.3)-298 (8.03)
Housewife/unemployed188 (9)1390 (85.5)1578 (42.53)
Free926 (44.4)74 (4.6)1000 (26.95)
Soldier/student177 (8.5)81 (5)258 (6.95)
Retired17 (0.8)-17 (0.45)
Having any kind of sexual contact1752 (78.1)962 (63.5)2714 (69.96)
Age34.75 ± 8.7933.81 ± 8.9134.28 ± 8.85

Of the people who were referred to the physician, 3.52% had a history of premarital sex, and 3.96% had a history of extramarital sex. Additionally, 34.17% of the participants reported using condoms during intercourse. Of the total participants, 13.62% reported a history of anal sex, and 12.90% reported a history of oral sex (Table 3).

Table 3.

Demographic Characteristics of People with Symptoms Who Referred to the Physician

VariablesPopulation MenWomenTotal
Job
Selfe employed32 (51.60)6 (3.65)38 (16.81)
Unemployed8 (13)1 (0.6)9 (3.98)
Student/soldier3 (4.3)8 (4.8)11 (4.86)
Housewife/worker13 (30.96)149 (90.53)162 (71.68)
Farmer/rancher6 (9.67)-6 (2.65)
History of sexually transmitted diseases
Yes4 (6.45)8 (5)12 (4.30)
Age31 ± 12.1227.50 ± 13.229.25 ± 12.66
Received treatment3 (75)4 (9.8)7 (58.33)
Sexual status
With spouse only44 (71)139 (84.2)183 (80.61)
Before marriage sex6 (9.67)2 (1.2)8 (3.52)
Extramarital affair8 (12.9)1 (.06)9 (3.96)
Homosexuality---
Have no sex4 (6.5)23 (13.9)27 (11.89)
Average sex per week1.47 ± 0.971.74 ± 1.031.60 ± 1.01
Number of sexual partners1.58 ± 31 ± 0.121.29 ± 1.56
Anal intercourse
Yes9 (15)29 (18.6)38 (13.62)
Oral sex
Yes9 (14.5)27 (17.3)36 (12.90)
Method of prevention
Condom13 (28.88)27 (26.2)40 (34.18)
Tablet 3 (6.6)12 (11.65)15 (12.82)
IUD4 (8.8)6 (5.89)10 (8.54)
Tubectomy and vasectomy9 (20)13 (12.62)22 (18.80)
Natural16 (35.55)27 (26.2)30 (25.64)
A history of sexually transmitted disease in the sexual partner
Yes11 (20)8 (5.8)19 (6.81)

4.2. Positive Predictive Value

The results showed that, in general, the clinical-based PPV for STI syndromes in men and women are 67.74 (62.34 - 73.14) and 85.36 (82.76 - 87.96), respectively. In men, the highest PPV is associated with abnormal discharge from the anus, 32.35 (25.35 - 39.35), and in women, it is related to the presence of abnormal secretions from the cervix, 59.39 (56.39 - 62.39). The laboratory-based PPV of STI syndromes is 0 for men and 5.04 (3.04 - 7.4) for women (Table 4).

Table 4.

Positive Predictive Value (Clinical and Laboratory) of Syndromes

VariablesSelf-reporting N (PCI for P)Doctor's Examination aConfirmed by a Physician Clinically PPV%Laboratory Based; PPV%
Men
Skin rash17 (0.76) (0.44 - 1.21)3 (4.84) (1.01 - 13.50)17.64 (8.6 - 26.4)-
Genital/perineal/perianal warts000-
Ulcers in the genital area7 (0. 3) (0.13 - 0.64)1 (1.61) (0.04 - 8.66)14.28 (4.28 - 24.28)-
Enlargement of the lymph nodes in the groin000-
Enlargement of lymph nodes in areas other than the groin000-
The presence of abnormal secretions from the genital tract107 (4.77) (3.93 - 5.74)18 (29.03) (18.20 - 41.95)16.82 (13.82 - 19.82)-
Swelling or redness of the scar52 (2.32) (1.74 - 3.03)9 (14.52) (6.86 - 25.78)17.30 (13.3 - 21.03)-
Abnormal discharge from the anus34 (1.52) (1.05 - 2.11)11 (17.74) (9.20 - 29.53)32.35 (25.35 - 39.35)-
Total for all syndromes217 (9.67) (8.48 - 10.97)42 (67.74) (54.66 - 79.09)67.74 (62.34 - 73.14)0
Total2243624219
Women
Skin rash20 (1.22) (0.75 - 1.88)5 (3.05) (1 - 6.97)25 (6.90 - 34.4)-
Genital/perineal/perianal warts5 (0.31) (0.10 - 0.71)2 (1.23) (0.15 - 4.39)4 (1.30 - 6.7)-
Ulcers in the genital area46 (2.81) (2.06 - 3.73)19 (11.59) (7.12 - 17.50)41.30 (37.9 - 44.7)-
Enlargement of the lymph nodes in the groin26 (1.59) (1.04 - 2.32)6 (3.66) (0.13 - 7.89)23.07 (15.37 - 30.77)-
Enlargement of lymph nodes in areas other than the groin17 (1.04) (0.61 - 1.66)90 (54.88) (46.93 - 62.65)23.52 (13.27 - 33.72)-
Abnormal discharge from the vagina b201 (12.28) (10.73 - 13.97)79 (48.17) (40.31 - 56.09)42.85 (39.85 - 45.85)-
Abnormal secretions from the cervix b133 (8.12) (6.85 - 9.55)6 (3.66) (1.35 - 7.79)59.39 (56.39 - 62.39)-
Abnormal discharge from the anus13 (0.79) (0.42 - 1.35)31 (19.14) (13.39 - 26.05)46.15 (32.45 - 59.85)-
Cervical examination result (abnormal)----
Bimanual examination result (abnormal)----
Total for all syndromes461 (28.16) (25.99 - 30.41)140 (85.37) (79.01 - 90.39)85.36 (82.76 - 87.96)5.04 (3.04-7.4)
Total1637164140109

5. Discussion

The current study is the first of its kind to assess the accuracy of symptom-based monitoring of STIs in Iran. A significant number of participants in the sample reported experiencing the defined symptoms, with a higher prevalence of symptoms observed among female participants.

The results of our study suggest that the self-reported symptom-based PPV in the population was considerably low, especially in men. This indicates that approximately 32.66% of individuals who reported symptoms did not have the disease based on the physician’s physical examination. Since the PPV of any test is influenced by the prevalence of the disease in a given population, the accuracy of symptom-based diagnosis is heavily dependent on the infection prevalence. Using a syndrome-based diagnosis strategy is more effective when the prevalence of infections is high (3, 8, 10).

The PPV based on laboratory test results in this study was extremely low. In other words, about 95% of individuals diagnosed as positive through symptom-based medical examination were negative in laboratory testing. This low predictive value results in a large number of individuals being falsely diagnosed as positive, leading to inappropriate treatment (11). This, in turn, contributes to increased antibiotic resistance, financial burden (12), and the stigma and social discrimination associated with STIs (12-14).

5.1. Strengths and Limitations

This is a population-based survey with a relatively large sample size. One of the most significant limitations in studying STIs is the high social stigma surrounding these diseases (8), which may reduce participation rates and lead to reporting bias in the study. Additionally, a substantial percentage of STI cases are asymptomatic, and because asymptomatic individuals were not examined in this study, there is a possibility that the findings may underestimate the true prevalence of STIs (14, 15).

5.2. Conclusions

The clinical and laboratory PPV of symptom-based STI management in the study population is alarmingly low. Therefore, the syndrome-based approach is not a suitable method for screening or monitoring STIs in the general population. However, this method may be more appropriate if used in high-risk groups where access to and cooperation with diagnostic facilities is severely limited.

Acknowledgements

References

  • 1.

    Garrett NJ, McGrath N, Mindel A. Advancing STI care in low/middle-income countries: has STI syndromic management reached its use-by date? Sex Transm Infect. 2017;93(1):4-5. [PubMed ID: 27084840]. [PubMed Central ID: PMC5505769]. https://doi.org/10.1136/sextrans-2016-052581.

  • 2.

    Workowski KA, Bolan GA, Centers for Disease C; Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137. [PubMed ID: 26042815]. [PubMed Central ID: PMC5885289].

  • 3.

    Shahesmaeili A, Karamouzian M, Shokoohi M, Kamali K, Fahimfar N, Nadji SA, et al. Symptom-Based Versus Laboratory-Based Diagnosis of Five Sexually Transmitted Infections in Female Sex Workers in Iran. AIDS Behav. 2018;22(Suppl 1):19-25. [PubMed ID: 29744768]. [PubMed Central ID: PMC6226376]. https://doi.org/10.1007/s10461-018-2130-5.

  • 4.

    Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis. 2017;17(8):e235-79. [PubMed ID: 28701272]. https://doi.org/10.1016/S1473-3099(17)30310-9.

  • 5.

    Sherrard J, Wilson J, Donders G, Mendling W, Jensen JS. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258-72. [PubMed ID: 30049258]. https://doi.org/10.1177/0956462418785451.

  • 6.

    Workowski KA. Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis. 2015;61 Suppl 8:S759-62. [PubMed ID: 26602614]. https://doi.org/10.1093/cid/civ771.

  • 7.

    Bote MM, Bedre RC, Solanki HB, Shenoy AG, Suryawanshi SR. Syndromic diagnosis vs. laboratory diagnosis of reproductive tract infections among married women of reproductive age group in urban slum of Mumbai. National Journal of Community Medicine. 2015;6(4):513-8.

  • 8.

    Mousavi MS, Fararouei M, Afsar-Kazerooni P, Nasirian M, Ghaem H. Evaluation of Conducting Phone Interviews on Sexual Behavior: An Iranian Population-Based Study. Shiraz E-Med J. 2022;23(6). https://doi.org/10.5812/semj-118708.

  • 9.

    Mousavi M, Fararouei M, Kazerooni PA, Nasirian M, Ghaem H. Population based estimation of point and period prevalence of sexully transmitted infections based the iranian symptoms surveillance system. Amazonia Investiga. 2019;8(18):29-42.

  • 10.

    Zemouri C, Wi TE, Kiarie J, Seuc A, Mogasale V, Latif A, et al. The Performance of the Vaginal Discharge Syndromic Management in Treating Vaginal and Cervical Infection: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(10). e0163365. [PubMed ID: 27706174]. [PubMed Central ID: PMC5052075]. https://doi.org/10.1371/journal.pone.0163365.

  • 11.

    Shaukat S, Kazmi AH. Sexually transmitted infections and syndromic management. Journal of Pakistan Association of Dermatologists. 2015;25(3):159-61.

  • 12.

    Shrivastava SR, Shrivastava PS, Ramasamy J. Utility of syndromic approach in management of sexually transmitted infections: public health perspective. J Coastal Life Med. 2014;2(1):7-13.

  • 13.

    Olaleye AO, Babah OA, Osuagwu CS, Ogunsola FT, Afolabi BB. Sexually transmitted infections in pregnancy - An update on Chlamydia trachomatis and Neisseria gonorrhoeae. Eur J Obstet Gynecol Reprod Biol. 2020;255:1-12. [PubMed ID: 33059307]. https://doi.org/10.1016/j.ejogrb.2020.10.002.

  • 14.

    Mlisana K, Naicker N, Werner L, Roberts L, van Loggerenberg F, Baxter C, et al. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis. 2012;206(1):6-14. [PubMed ID: 22517910]. [PubMed Central ID: PMC3490689]. https://doi.org/10.1093/infdis/jis298.

  • 15.

    Smith L, Angarone MP. Sexually Transmitted Infections. Urol Clin North Am. 2015;42(4):507-18. [PubMed ID: 26475947]. https://doi.org/10.1016/j.ucl.2015.06.004.